Finance

Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.

As fundamentals improve, potential rate plateau could ignite growth.

Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.

Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.

Biotech stocks and the indexes have staged an impressive recovery.

Barnes discusses alternative reimbursement plans for expensive, one-off therapies.

A review of pharma and biotech equity market, IPO, and M&A trends and outputs through the first half of 2022—and implications for the future as disruptions continue to have an impact.

A look at the driving factors behind renewed optimism.

A recent analysis of the biotech market shows promising signs.

Kobel discusses taking a company public during a challenging time in the market.

COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.

A summary of key takeaways from EY’s new Beyond Borders report.

Restructuring and ensuring the right talent is in place can help life sciences industry push through latest downward spiral.

Some observations point to hope for an upturn.

Living to fight another day, as potential investment spark looms.

What will current stranglehold mean for industry down the line?

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

But a doubling-down on R&D offers reason for optimism.

Biopharma stock performance continues to struggle.

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Ahead of the release of EY’s annual M&A Firepower report this week, Pharm Exec talks to EY’s Arda Ural to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.

Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.

Industry growth in innovation could spark financial rebound.

Regulatory headwinds are poised to ease as new year approaches.